Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lisata TherapeuticsLSTA -3.86%32 3-Year EBITDA Growth Rate is 42.80% as of Jun. 2026, which is 35% above its 10-year median of 31.70. GuruFocus rates LSTA with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,129 Biotechnology companies, Lisata Therapeutics ranks better than 80.25% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 35.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 35.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lisata Therapeutics was 57.80% per year. The lowest was 7.10% per year. And the median was 31.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lisata Therapeutics 3-Year EBITDA Growth Rate Related Terms
LSTA vs CYCN, OSRH, ICU: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Lisata Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lisata Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lisata Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.80% mean?
Lisata Therapeutics (LSTA) has a 3-Year EBITDA Growth Rate of 42.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lisata Therapeutics and its competitors. This is 35% above median its historical median of 31.70. Over the past decade, Lisata Therapeutics' 3-Year EBITDA Growth Rate has ranged from 7.10 to 57.80. According to the industry distribution chart, Lisata Therapeutics ranks #223 out of 1129 companies in the Biotechnology industry, placing it in the top 19.8%.
Is Lisata Therapeutics' 3-Year EBITDA Growth Rate too high?
Lisata Therapeutics' current 3-Year EBITDA Growth Rate of 42.80% is 35% above median its 10-year median of 31.70. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 57.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Lisata Therapeutics' value of 42.80% is 191.2% above this industry median. Based on the distribution chart, Lisata Therapeutics ranks #223 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lisata Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' 3-Year EBITDA Growth Rate compare to CYCN and OSRH?
According to the Biotechnology industry distribution chart, Lisata Therapeutics ranks #223 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Lisata Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Lisata Therapeutics' value of 42.80% is 191.2% above this benchmark. Historically, Lisata Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 7.10 to 57.80 over the past decade. While the company's 10-year median is 31.70 vs. the industry median of 14.70, Lisata Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lisata Therapeutics's current 3-Year EBITDA Growth Rate of 42.80% is 191.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lisata Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lisata Therapeutics's current 3-Year EBITDA Growth Rate is 42.80%, which is 35% above median its own 10-year median of 31.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (LSTA) has a current 3-Year EBITDA Growth Rate of 42.80%. The current 3-Year EBITDA Growth Rate is 42.80%, which is 35% above median its 10-year median of 31.70 and 191.2% above the Biotechnology industry median of 14.70. Lisata Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lisata Therapeutics (LSTA), the current 3-Year EBITDA Growth Rate is 42.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
32GF Score
Get the complete analysis for LSTA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSTA has been successfully added to your 
